Krajina: Švajčiarsko
Jazyk: taliančina
Zdroj: Swissmedic (Swiss Agency for Therapeutic Products)
rituximabum
Sandoz Pharmaceuticals AG
L01FA01
rituximabum
Concentrato per soluzione per Infusione
rituximabum 500 mg, acidum citricum monohydricum, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 50 ml.
A
Biotechnologika
Non-Hodgkin-Lymphom, Rheumatoide Artrite, ANCA-assoziierte Vasculite
zugelassen
2018-03-07